Neurocrine Biosciences
NBIX
NBIX
585 hedge funds and large institutions have $12.9B invested in Neurocrine Biosciences in 2024 Q1 according to their latest regulatory filings, with 89 funds opening new positions, 225 increasing their positions, 208 reducing their positions, and 47 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
3% more capital invested
Capital invested by funds: $12.5B → $12.9B (+$399M)
2.54% less ownership
Funds ownership: 96.33% → 93.79% (-2.5%)
25% less funds holding in top 10
Funds holding in top 10: 12 → 9 (-3)
Holders
585
Holding in Top 10
9
Calls
$88M
Puts
$61.6M
Top Buyers
| 1 | +$101M | |
| 2 | +$77.2M | |
| 3 | +$73.6M | |
| 4 |
Invesco
Atlanta,
Georgia
|
+$63.9M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$47.5M |
Top Sellers
| 1 | -$357M | |
| 2 | -$92.8M | |
| 3 | -$76.5M | |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$76.5M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$51.7M |